Kompendium 2020 Forschung & Klinik

More documents

Info

TOP-Studien 60 Dr. Kevin Staats Statistical Analysis The competing risks analysis revealed cumulative revision incidences of 26% (95% CI, 20.3%-31.9%) at 12 months, 37.9% (95% CI, 31.3%-44.4%) at 24 months, 52.6% (95% CI, 45.1%-59.5%) at 5 years, and 58.2% (95% CI, 50.1%-65.4%) at 10 years for all patients in this study. Author: Kevin Staats started his residency at the Department of Orthopedics and Trauma Surgery at the Medical University of Vienna in 2016. His research interests are total joint replacement and revision arthroplasty and he is deputy director of the Arthroplasty Research Cluster. Dr. Staats was awarded the Ines Mandl Research Fellowship and had the opportunity to expand his clinical and research focus at the Hospital of Special Surgery/Weill Cornell University, New York City. His research on the antimicrobial effect of electrochemically modified titanium surfaces received institutional funding by CEST Wr. Neustadt through the FFG-COMET program. Dr. Staats is currently an extended board member of the Austrian Orthopedic Society as the representative for Austrian orthopedic residents. The multivariate analysis adjusted for important variables such as age, sex, disease (oncologic versus non-oncologic), cementation, and year of surgery clearly showed that patients with oncologic diagnoses have a lower risk of undergoing revision surgery than patients with non-oncologic diagnoses (HR 0.44 for oncologic versus non-oncologic; 95% CI, 0.22-0.87; p = 0.02). Additionally, the multivariate Fine and Gray model yielded an interaction between the two prognostic factors of oncologic disease and cementation (p = 0.03), revealing a reduction in the risk of revision with cemented fixation in patients with oncologic disease (HR 0.53; 95% CI, 0.29-0.98). According to our results, implant fixation may have a major impact on the risk of revision surgery in patients with oncologic disease. Cementation did not have any effect on the cumulative incidence of revision surgery for any cause in our overall cohort. However, cemented distal femoral replacements were less frequently revised because of aseptic loosening than cementless endoprostheses in patients who underwent surgery for oncologic indications (with an incidence of 6.9% (95% CI, 2.5%-14.3%) at 2 years and 8.6% (95% CI, 3.4%-16.8%) at 5 years, compared with 11.8% (95% CI, 7%- 17.9%) and 19.7% (95% CI, 13.2%-27.1%; p = 0.04), respectively. Due to the rate of aseptic loosening of cementless implants being almost 12% in the first two years, we believe that initial implant fixation or osseointegration was not achieved in patients with oncologic disease. In conclusion, this study is of vital importance since it is the first one to show the differences between patients with and without oncologic conditions undergoing DFR. Cementation might be a better fixation method for patients with oncologic condition, however further studies are needed to prove this hypothesis.
COPAL ® – ERFOLGREICH GEGEN INFEKTIONEN COPAL Bei infektionsgefährdeten Patienten & Revisionseingriffen ® G+C Heraeus unterstützt Die Wahl des richtigen Behandlungsalgorithmus ist ein bei COPAL der Therapie knee moulds mit COPAL Formen ® für temporäre Knie Spacer Knochenzement gesteigert. (1) PALAMIX ® duo Vakuummischsystem mit Sammeln essenzieller Erfolgsfaktor zur Prävention und Reduktion von periprothetischen Infektionen. Bei Revisionen – ob einzeitig bei guten Weichteilverhältnissen und bekannten sensiblen Erregern oder zweizeitig bei prekären Weichteilverhältnissen und unbekannten resistenten Pathogenen – wird die Effektivität Knochenzement sowie den COPAL ® knee moulds zur He rstellung artikulierender Knie-Spacer. Auch bei Primäreingriffen mit er höhtem Infektionsrisiko aufgrund von Komorbidiäten oder durch eine Schenkel hals fraktur als Traumafall unterstützen PALAMIX COPAL ® - Knochenzemente. Beschreibung (2) der Therapie durch den Einsatz von antibiotikahaltigem PALAMIX ® uno Vakuummischsystem mit Sammeln (bis 160 g Zement) COPAL ® Knochenzemente bieten: COPAL ® COPAL ® G+V COPAL ® spacem PALAMIX ® Schnorchel Slim PALAMIX ® Schnorchel Medium PALAMIX ® Zementpistole PALAMIX ® Vakuumpumpe Beschreibung Hochviskoser, röntgenpositiver Kno Hochviskoser, röntgenpositiver Kno Hochviskoser, röntgenpositiver Spe Schnorchel zur Applikation niedrig biegsamer, konischer Schnorchel; wiederverwendbare Applikationspi wiederverwendbare Vakuumpumpe Zweifach antibiotikahaltiger Knochenzement Implantatfixierung Effektiv auch gegen Anaerobier Breites Wirkspektrum gegen die für PPI klinisch relevanten Keime Infektions-Prävention bei Revisionseingriffen Hoher lokaler Wirkspiegel bei niedriger systemischer Belastung Effektiv auch gegen MRSA / MRSE Bestellen Sie einfach bei Heraeus. Deutschland: Tel.: + 49 (0) 6181 35 30 00 Fax: + 49 (0) 6181 35 33 66 Österreich: Tel.: + 43 (0) 1 5 22 25 80 Fax: + 43 (0) 1 5 22 25 81 (10) (1) Sprowson AP. et al. Bone Joint J. 2016. (11) (2) Engesaeter in Wahlenkamp. Local Antibiotics in arthroplasty. 2007, p. 152. www.heraeus-medical.com Heraeus Medical GmbH Philipp-Reis-Str. 8/13 61273 Wehrheim Germany Heraeus Medical Schweiz AG Mühlebachstrasse 72 8008 Zürich Switzerland
Page 1 and 2:
Kompendium 2020 Forschung & Klinik
Page 3 and 4:
Inhalt/Impressum 3 Die Klinik 4 Edi
Page 6 and 7:
Zahlen und Fakten 6 Klinische Leist
Page 9 and 10: Zahlen und Fakten 9 Hohe Ambulanzfr
Page 11 and 12: Klinik 11 Neben der Polytrauma-Vers
Page 13 and 14: Die Meniskusversorgung Alle Möglic
Page 15 and 16: Das ÄrztInnenteam 15 Universitäts
Page 17 and 18: Spherox ist das einzig EMA-zugelass
Page 19 and 20: Das ÄrztInnenteam 19 Medizinische
Page 21 and 22: Ambulanzen 21 Spezialambulanzen Kli
Page 23 and 24: TOP-Studien 23 defects (≤ Interna
Page 25 and 26: WE LENGTHEN, TRANSPORT AND GROW BON
Page 27 and 28: TOP-Studien 27 5 5 Patients (-) 10
Page 29 and 30: FRESH AIR FRESH PERSPECTIVE Remove
Page 31 and 32: TOP-Studien 31 Aseptic loosening is
Page 33 and 34: Integriertes Patientenversorgungsko
Page 35 and 36: TOP-Studien 35 Figure 1: Bone miner
Page 37 and 38: TOP-Studien 37 A Prediction Model f
Page 39 and 40: TOP-Studien 39 Figure 2: Graphic vi
Page 41 and 42: TOP-Studien 41 Figure 1: Individual
Page 43 and 44: 3D Biochips for Research on Inflamm
Page 45 and 46: TOP-Studien 45 Chondro-Synovial Cro
Page 47 and 48: TOP-Studien 47 Figure 1. (A) Intrao
Page 49 and 50: TOP-Studien 49 Total Hip Arthroplas
Page 51 and 52: TOP-Studien 51 nerve lesions (1 N.
Page 53 and 54: TOP-Studien 53 1 Volume fill of car
Page 55 and 56: TOP-Studien The Genetic Landscape o
Page 57 and 58: TOP-Studien 57 rare heterozygous lo
Page 59: TOP-Studien 59 Figure 1: Example of
Page 63 and 64: TOP-Studien 63 Figure 1: Biomechani
Page 65 and 66: TOP-Studien 65 Development of a New
Page 67 and 68: TOP-Studien 67 Table 1: Relative ro
Page 69 and 70: Publikationen 69 Bumberger A, Kolle
Page 71 and 72: Publikationen 71 sou NA, McNally MA
Page 73 and 74: Publikationen 73 Propensity-Matched
Page 75 and 76: Publikationen 75 novel hypothetical
Page 77 and 78: Publikationen 77 ritisches Denken.
Page 79 and 80: Publikationen 79 Zuteilungsdatum: 2
Page 81 and 82: Publikationen 81 Payr S: Reviewer J
Page 83 and 84: Publikationen 83 fracture, Wrist Ar
Page 85 and 86: Kundenkompetenzzentrum mit Shop & W
Page 87: ·
show all

Kompendium 2020 Forschung & Klinik

Create successful ePaper yourself

Delete template?

Save as template?